Synthesis and evaluation of the antiproliferative efficacy of BRM270 phytocomposite nanoparticles against human hepatoma cancer cell lines.


Journal

Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 03 05 2018
revised: 17 10 2018
accepted: 27 11 2018
entrez: 26 1 2019
pubmed: 27 1 2019
medline: 18 6 2019
Statut: ppublish

Résumé

BRM270 is the most leading phytochemical extract that possesses potent anticancer properties. A major challenge associated with this drug is its low bioavailability and thus requires high dosages for cancer treatment. Here, we report the novel nano-synthesis of phyto-composite, BRM270 for the first time by mechanical milling method with specific modifications for enhanced cytotoxicity against HepG2 human hepatoma cancer cells. Unlike free BRM270 and other phytomedicines, BRM270 nanoparticles (BRM270 NPs) are well-dispersed and small sized (23 to 70 nm) which is believed to greatly enhanced cellular uptake. Furthermore, the acidic tumor microenvironment attracts BRM270 NPs enhancing targeted therapy while leaving normal cells less affected. The comparative cytotoxicity analysis using MTT assay among the three treatment groups, such as free BRM270, BRM270 NPs, and doxorubicin demonstrated that BRM270 NPs induced greater cytotoxicity against HepG2 cells with an effective drug concentration of 12 μg/ml. From FACS analysis, we observed an apoptotic cell death of 44.4% at BRM270 NPs treated cells while only 12.5% found in the free BRM270 treated cells. Further, the comparative relative expression profiling of the candidate genes were showed significant (p < 0.05) down-regulation of IL6, BCL2, p53, and MMP9 in the BRM270 NPs treated cells, compared to the free BRM270 and doxorubicin. Indeed, the genes, CASPASE 9 and BAX have shown significant (p < 0.05) upregulation in cells treated with BRM270 NPs as compared to counter treatment groups. The investigation of the signal pathways and protein-protein network associations were also carried out to elucidate the functional insights underlying anti-cancer potential of BRM270 NPs in HepG2 cells. Taken together, our findings demonstrated that these uniquely engineered BRM270 NPs effectively enter into the cancer cells due to its acidic microenvironment thereby inducing apoptosis and regulate the cell-proliferation in-vitro at extremely low dosages.

Identifiants

pubmed: 30678901
pii: S0928-4931(18)31253-0
doi: 10.1016/j.msec.2018.11.055
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Drugs, Chinese Herbal 0
Jiedu Xiaozheng Yin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-176

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Meeta Gera (M)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Nameun Kim (N)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Mrinmoy Ghosh (M)

Department of Biotechnology, Division of Research and Development, Lovely Professional University, Punjab 144411, India.

Neelesh Sharma (N)

Division of Veterinary Medicine, Faculty of Veterinary Science and Animal Husbandry, Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu, R.S. Pura, Jammu 181102, India.

Do Luong Huynh (DL)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Nisansala Chandimali (N)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Hyebin Koh (H)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Jiao Jiao Zhang (JJ)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Tae Yoon Kang (TY)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Yang Ho Park (YH)

BRM Institute, Seoul 06111, Republic of Korea.

Taeho Kwon (T)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea.

Dong Kee Jeong (DK)

Laboratory of Animal Genetic Engineering and Stem Cell Biology, Department of Animal Biotechnology, Jeju National University, Jeju, Jeju-Do 690-756, Republic of Korea. Electronic address: newdkjeong@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH